In addition to BRAF-specific inhibition with vemurafenib and dabrafenib, the MEK1/2 inhibitor trametinib is also approved for the treatment of metastatic or unresectable BRAF V600-mutant melanoma [13–16]. The gene discussed is BRAF; the disease is melanoma.